½ÃÀ庸°í¼
»óÇ°ÄÚµå
1422958
G´Ü¹éÁú °áÇÕ ¼ö¿ëü(GPCR) ½ÃÀå : Á¦Ç°º°, ºÐ¼® À¯Çüº°, ¿ëµµº°, Áö¿ªº°(2024-2032³â)G-Protein Coupled Receptors Market by Product, Assay Type, Application, and Region 2024-2032 |
¼¼°è G´Ü¹éÁú °áÇÕ ¼ö¿ëü(GPCR) ½ÃÀå ±Ô¸ð´Â 2023³â 34¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2024³âºÎÅÍ 2032³â±îÁö 5.69%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)·Î 2032³â±îÁö 57¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óÇÏ°í ÀÖ½À´Ï´Ù. ½Å¾à °³¹ß¿¡¼ GPCRÀÇ Ã¤Åà Áõ°¡, ¾Ï ȯÀÚ ¼ö Áõ°¡, ±¤¹üÀ§ÇÑ Á¶»ç °³¹ß(R&D) È°µ¿Àº ½ÃÀåÀ» À̲ô´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù.
G´Ü¹éÁú °áÇÕ ¼ö¿ëü(GPCR)´Â Àΰ£ °Ô³ð¿¡ ¾ÏȣȵǾî ÀÖ´Â °¡Àå Å« ´Ü¹éÁú ±ºÀ¸·Î, ¼¼Æ÷¿¡ ½ÅÈ£¸¦ Àü´ÞÇÏ´Â ½ÅÈ£ Àü´Þ ºÐÀÚ·Î ¼¼Æ÷ ¿ÜºÎÀÇ ÀÚ±ØÀ» ¼¼Æ÷ ³» ¹ÝÀÀÀ¸·Î ÀüȯÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϸç, ¼¼Æ÷¸·¿¡ Á¸ÀçÇÏ°í ¸ðµç »ý¸®Àû °úÁ¤¿¡ °ü¿©ÇÑ´Ù, GPCRÀº ¼¼Æ÷ Ç¥¸éÀÇ ¼ö¿ëü·Î ÁöÁú, ´ç, ºû ¿¡³ÊÁö, ÆéŸÀ̵å, ´Ü¹éÁú ÇüÅÂÀÇ ¸Þ½ÃÁö ¼ö½Å±â ¿ªÇÒÀ» ÇÏ´Â ¼¼Æ÷¸·¿¡ Á¸ÀçÇÏ¸ç ¸ðµç »ý¸®Àû °úÁ¤¿¡ °ü¿©ÇÕ´Ï´Ù. ÀÌ ¼ö¿ëü´Â ¿°Áõ¼º Áúȯ, ´ë»ç ÀÌ»ó, ½ÉÀå Áúȯ, ¾Ï, ´Ü¹ß¼º Áúȯ µî ´Ù¾çÇÑ ÁúȯÀÇ Ä¡·á¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ±× °á°ú GPCRÀº Æ÷À¯·ù, ½Ä¹°, ¹Ì»ý¹°, ¹«Ã´Ãßµ¿¹°À» Æ÷ÇÔÇÑ ¿©·¯ »ý¹°ÀÇ ¼¼Æ÷¸·¿¡µµ Á¸ÀçÇÕ´Ï´Ù.
Àü ¼¼°èÀûÀ¸·Î ½Å¾à°³¹ß¿¡ GPCRÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÏ°í ÀÖ´Â °ÍÀÌ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ÀÌ¿¡ µû¶ó ¾Ï ȯÀÚ ¼ö Áõ°¡¿Í ½ÉÇ÷°ü °¨¿°, È£Èí°ï¶õ°ú °°Àº »ýÈ°½À°üº´ Áõ°¡·Î ÀÎÇØ ½Å¾à °³¹ß¿¡ GPCRÀÌ ±¤¹üÀ§ÇÏ°Ô È°¿ëµÇ°í ÀÖ´Â °ÍÀÌ ½ÃÀå ¼ºÀåÀ» °ßÀÎÇÏ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, GPCRÀº ¼¼Æ÷ Ç¥¸é¿¡ Á¸ÀçÇϱ⠶§¹®¿¡ ´Ù¾çÇÑ ÈÇÐ ¹°Áú°ú »ý¹°ÇÐÀû ¾à¹°·Î Á¶ÀýÇÒ ¼ö ÀÖÀ¸¸ç, ¿©·¯ »ý¸®Àû °úÁ¤¿¡¼ GPCRÀÇ ±¤¹üÀ§ÇÑ Àû¿ëÀº ¶Ç ´Ù¸¥ ¼ºÀå ÃËÁø¿äÀÎÀ¸·Î ÀÛ¿ëÇÏ°í ÀÖ½À´Ï´Ù. ÀÌ¿Í´Â º°µµ·Î, ÀÚµ¿È ¹× Çõ½Å ±â¼úÀ» ÀǾàÇ° °³¹ß ½ºÅ©¸®´× ÀýÂ÷¿¡ ÅëÇÕÇÏ¿© Ä¡·áÁ¦ÀÇ »ý»ê ´É·ÂÀ» Çâ»ó½ÃÅ°´Â °ÍÀÌ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½Å¾àÀÇ ¼ö¿ëü ±¸Á¶¿Í Á¦Çüȸ¦ °£¼ÒÈÇϱâ À§ÇÑ °è»êÀû Á¢±Ù¹ýÀÇ ¹ßÀü°ú °°Àº È¿°úÀûÀÎ ½Å¾à °³¹ß ¹æ¹ý·ÐÀÌ Å©°Ô ¹ßÀüÇÏ¸é¼ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¾¾çÇÐ, ħÀ±, ÀüÀÌ, À¯ÁÖ, Ç÷°ü ÀçÇü¼º µî ¾Ï »ý¹°ÇÐÀÇ ´Ù¾çÇÑ Ãø¸é¿¡¼ GPCRÀÌ ±¤¹üÀ§ÇÏ°Ô »ç¿ëµÇ°í ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀå¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¾¾ç ÀüÀÌ ¹× Áõ½ÄÀ» Çص¶ÇÏ°í È¿°úÀûÀÎ Ä¡·á¹ýÀ» °³¹ßÇϱâ À§ÇØ GPCRÀÇ »ç¿ëÀÌ Áõ°¡ÇÏ°í ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ´Ù¸¥ ¿äÀÎÀ¸·Î´Â ±¤¹üÀ§ÇÑ Á¶»ç °³¹ß(R&D) È°µ¿, ´Ù¾çÇÑ ÀÚµ¿È °³¼±, cAMP(cyclic adenosine monophosphate)ÀÇ ±¤¹üÀ§ÇÑ Ã¤ÅÃ, »ý¸í °øÇÐ ¹× ¹ÙÀÌ¿À ÀǾàÇ° ºÐ¾ß¿¡¼ ´Ù¾çÇÑ Á¤ºÎ À̴ϼÅƼºêÀÇ ±¸Çö µîÀÌ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
The global G-protein coupled receptors (GPCRs) market size reached US$ 3.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.7 Billion by 2032, exhibiting a growth rate (CAGR) of 5.69% during 2024-2032. The increasing adoption of GPCRs in drug discovery, the rising number of cancer cases, and extensive research and development (R&D) activities represent some of the key factors driving the market.
G-protein-coupled receptors (GPCRs) are the largest protein family encoded by the human genome. They are signal-transducing molecules that transmit signals to cells and play a key role in converting an extracellular stimulus into intracellular responses. They are located in the cell membrane and are responsible for all physiological processes. GPCRs are cell surface receptors that act like an inbox for messages in the form of lipids, sugars, light energy, peptides, and proteins. These receptors are widely used in the treatment of various diseases, such as inflammatory disorders, metabolic imbalances, cardiac disorders, cancer, and monogenic disorders. As a result, GPCRs are also found in the cell membranes of several organisms, including mammals, plants, microorganisms, and invertebrates.
The increasing adoption of GPCRs in drug discovery across the globe is one of the key factors driving the market growth. In line with this, the widespread utilization of GPCRs in the development of novel pharmaceuticals due to the rising number of cancer cases and lifestyle-related diseases, such as cardiovascular infections and respiratory difficulties, are favoring the market growth. Moreover, the extensive application of GPCRs in several physiological processes as they can be modulated by a wide range of chemical or biological agents due to their cell-surface location is acting as another growth-inducing factor. Apart from this, the integration of automation and innovative technologies with drug development screening procedures to improve their capabilities in therapeutic production is providing an impetus to the market growth. Furthermore, significant developments in effective drug discovery methods, such as advancements in the computational approaches to streamline receptor structure and formulation of new drugs, are propelling the market growth. Additionally, the widespread adoption of GPCRs in oncology and various aspects of cancer biology, such as invasion, migration, and vascular remolding, is providing a considerable boost to the market growth. Besides this, the increasing utilization of GPCRs for decoding metastasis and growth of tumors and developing effective lines of treatment is positively influencing the market growth. Other factors, including extensive research and development (R&D) activities, various automation improvements, the widespread adoption of cyclic Adenosine Monophosphate (cAMP), and the implementation of various government initiatives in the biotechnology and biopharmaceutical sector are anticipated to drive the market growth.
IMARC Group provides an analysis of the key trends in each segment of the global G-protein coupled receptors (GPCRs) market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on product, assay type, and application.
Cell Lines
Detection Kits
Cell Culture Reagents
Ligands
The report has provided a detailed breakup and analysis of the G-protein coupled receptors (GPCRs) market based on the product. This includes cell lines, detection kits, cell culture reagents and ligands. According to the report, cell lines represented the largest segment.
cAMP Functional Assays
Calcium Functional Assays
B-Arrestin Functional Assays
Radioligand Binding and GTPγS Functional Assays
Internalization Assays
Trafficking Assays
Others
The report has provided a detailed breakup and analysis of the G-protein coupled receptors (GPCRs) market based on the assay type. This includes cAMP functional, calcium functional, B-Arrestin functional, radioligand binding and GTPγS functional, internalization, and trafficking assays. According to the report, cAMP functional assays represented the largest segment.
Cancer Research
CNS Research
Metabolic Research
Cardiovascular Research
Inflammation Research
Respiratory Research
Others
The report has provided a detailed breakup and analysis of the G-protein coupled receptors (GPCRs) market based on the application. This includes cancer, CNS, metabolic, cardiovascular, inflammation, respiratory research, and others. According to the report, cancer research represented the largest segment.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for G-protein coupled receptors (GPCRs). Some of the factors driving the North America G-protein coupled receptors (GPCRs) market included rising number of cancer cases, extensive research and development (R&D) activities, and various automation improvements.
The report has also provided a comprehensive analysis of the competitive landscape in the global G-protein coupled receptors (GPCRs) market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abcam plc, Becton Dickinson and Company, Enzo Biochem Inc., Eurofins DiscoverX Products LLC, HD Biosciences Co. Ltd. (WuXi AppTec), Merck KGaA, Molecular Devices LLC (Danaher Corporation), PerkinElmer Inc., Promega Corporation, Thermo Fisher Scientific Inc., etc.